This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ruat, C.
Right arrow Articles by Osterhaus, A. D. M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ruat, C.
Right arrow Articles by Osterhaus, A. D. M. E.

 Previous Article  |  Next Article 

Journal of Virology, March 2008, p. 2565-2569, Vol. 82, No. 5
0022-538X/08/$08.00+0     doi:10.1128/JVI.01928-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Vaccination of Macaques with Adjuvanted Formalin-Inactivated Influenza A Virus (H5N1) Vaccines: Protection against H5N1 Challenge without Disease Enhancement{triangledown}

Caroline Ruat,1 Catherine Caillet,1 Alexandre Bidaut,2 James Simon,3 and Albert D. M. E. Osterhaus4*

Research Department, sanofi pasteur, Marcy L'Etoile, France,1 Aventis-Pharma, Sanofi-Aventis, Alfortville, France,2 ViroClinics BV, Rotterdam, The Netherlands,3 Erasmus Medical Center, Rotterdam, The Netherlands4

Received 4 September 2007/ Accepted 12 December 2007

We investigated the ability of adjuvanted, inactivated split-virion influenza A virus (H5N1) vaccines to protect against infection and demonstrated that the disease exacerbation phenomenon seen with adjuvanted formaldehyde-inactivated respiratory syncytial virus and measles virus investigational vaccines did not occur with these H5N1 vaccines. Macaques were vaccinated twice with or without an aluminum hydroxide or oil-in-water emulsion adjuvanted vaccine. Three months later, animals were challenged with homologous wild-type H5N1. No signs of vaccine-induced disease exacerbation were seen. With either adjuvant, vaccination induced functional and cross-reactive antibodies and protected the lungs and upper respiratory tract. Without an adjuvant, the vaccine provided partial protection. Best results were obtained with the emulsion adjuvant.

* Corresponding author. Mailing address: Erasmus Medical Center, Rotterdam, The Netherlands. Phone: 31-10-4088066. Fax: 31-10-4089485. E-mail: a.osterhaus{at}erasmusmc.nl

{triangledown} Published ahead of print on 19 December 2007.

Journal of Virology, March 2008, p. 2565-2569, Vol. 82, No. 5
0022-538X/08/$08.00+0     doi:10.1128/JVI.01928-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Laddy, D. J., Yan, J., Khan, A. S., Andersen, H., Cohn, A., Greenhouse, J., Lewis, M., Manischewitz, J., King, L. R., Golding, H., Draghia-Akli, R., Weiner, D. B. (2009). Electroporation of Synthetic DNA Antigens Offers Protection in Nonhuman Primates Challenged with Highly Pathogenic Avian Influenza Virus. J. Virol. 83: 4624-4630 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»